Design Therapeutics (DSGN) Net Cash Flow (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Net Cash Flow data on file, last reported at -$4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 54.07% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$897000.0 (up 94.3% YoY), and the FY2025 full-year result was -$5.7 million, down 518.71% from the prior year.
• Net Cash Flow declined to -$4.1 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $16.3 million in Q2 2024 to a low of -$167.7 million in Q2 2022.
• A 5-year average of -$16.8 million and a median of -$4.6 million in 2025 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 994.73% in 2024, while the deepest fall reached 2163.22% in 2024.
• Tracing DSGN's Net Cash Flow over 5 years: stood at -$16.0 million in 2022, then surged by 57.91% to -$6.7 million in 2023, then retreated by 15.17% to -$7.8 million in 2024, then jumped by 122.77% to $1.8 million in 2025, then sank by 331.11% to -$4.1 million in 2026.
• Business Quant data shows DSGN's Net Cash Flow at -$4.1 million in Q1 2026, $1.8 million in Q4 2025, and -$4.6 million in Q3 2025.